A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma

Bevacizumab for Recurrent Glioblastoma Multiforme: A Meta-Analysis

(2017) Eric T. Wong et al.   Journal of the National Comprehensive Cancer Network

Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma

(2011) Jonathan Verma et al.   CANCER

Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma

(2011) David A. Reardon et al.   JOURNAL OF NEURO-ONCOLOGY

Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma

(2010) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of sunitinib malate in patients with recurrent high-grade glioma

(2010) B. Neyns et al.   JOURNAL OF NEURO-ONCOLOGY

MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib

(2010) Manik Chahal et al.   NEURO-ONCOLOGY

NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

(2009) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma

(2008) Marc C. Chamberlain et al.   JOURNAL OF NEURO-ONCOLOGY

Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model

(2008) Qingyu Zhou et al.   NEURO-ONCOLOGY

Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence

(2008) A. D. Norden et al.   NEUROLOGY